JPRN-jRCT2080225304已完成2 期
A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor
Hisato Kawakami (Coordinating Investigator)0 个研究点目标入组 28 人开始时间: 2020年8月6日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Subjects must have histologically confirmed adenocarcinoma of gastric or esophago-gastric junction.
- •2.Subject must have unresectable advanced, recurrent or metastatic gastric or esophago-gastric junction adenocarcinoma.
- •3.Subjects must have confirmed MSI-H.
- •4.Subjects must not be amenable to curative approaches such as definitive chemoradiation and/or surgery.
- •5.No prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease.
- •6.ECOG performance status of 0 or 1..
排除标准
- •1.Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before enrollment.
- •2.Subjects who received radiation therapy for local control or pain control within 14 days prior to enrollment.
- •3.Subjects who received blood transfusion or hematopoietics within 14 days prior to enrollment.
- •4.Other prior malignancy requiring active treatment within the previous 3 years from enrollment .
研究者
相似试验
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502909-15-00477
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001928-54-DEBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
A Study to Evaluate Preliminary Efficacy of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-ESBristol-Myers Squibb International Corporation495
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men, with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001928-54-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO497